Next-generation therapies to outsmart drug-resistant lung cancer
“The Gray Lab is developing next-gen therapies, including protein degraders and “dual-grip” inhibitors, to overcome drug resistance in lung cancer.”
PFOS, PFHA, Mono-Iso-Nonyl-Phthalate Can Predict Lung Cancer Mortality
“Researchers observed associations for higher circulating levels of PFOS, PFHA, and mono-iso-nonyl-phthalate with an increased risk for lung cancer death, but not with lung cancer incidence.”
Embryonic proteins reactivated in lung tumors may drive faster growth
“Researchers have uncovered how proteins normally active only before birth can drive aggressive lung cancer, opening new avenues for future treatments. The study found that more aggressive lung cancers switch on a pair of embryonic proteins (proteins not usually found in healthy adult cells), resulting in poorer patient outcomes.”
VATS vs Open Lobectomy in Early-Stage Lung Cancer: Survival Meta-Analysis Shows Overall Survival Benefit
“A new individual patient data meta-analysis provides the strongest answer to date. By pooling patient-level data from all eligible randomized trials, the investigators found that VATS lobectomy was associated with a 21% reduction in the risk of death compared with open lobectomy, with no compromise in disease-free survival (Harris et al., 2026). These results strengthen the scientific rationale for prioritizing VATS when technically feasible in patients with early-stage NSCLC.”
AI-driven technology does not speed up lung cancer diagnosis
“The LungIMPACT trial, the largest randomised trial of its kind and led from UCLH, ran across five NHS trusts in England and found no significant reduction in the time from X-ray to cancer diagnosis when AI flagged abnormal scans so that a radiologist could prioritise these for early review. The study, published today in Nature Medicine, only tested the impact of AI prioritisation and did not change the usual care pathway.”
Barry Manilow Details Lung Cancer Diagnosis and Treatment, Says It ‘Made Me Take Stock of My Life’ at 82 (Exclusive)
““You just don’t even think about [how fragile life is]. And suddenly, you have lung cancer. But I’m still here. I’m not all here; there’s part of me that isn’t here — they took out a part of me, and now I’ve got to figure out, ‘What do I do?’” Manilow says.”
Sunvozertinib Monotherapy Bests Platinum-Doublet Chemotherapy in EGFR Exon 20+ NSCLC
“Key Takeaways: Phase 3 WU-KONG28 randomized treatment-naïve stage IIIB/IIIC/IV nonsquamous NSCLC with confirmed EGFR exon 20 insertions to sunvozertinib 300 mg daily or carboplatin/pemetrexed ± pemetrexed maintenance. Blinded independent central review–assessed PFS per RECIST 1.1 was the primary end point, and overall survival was a key secondary end point in this confirmatory global program.”
Acute and Lifelong Exercise Modulate the Tumorigenic Potential of Human Lung Cancer Cells and Their Susceptibility to Cisplatin
“Significantly, we showed, for the first time, that lifelong exercise increased susceptibility to a chemotherapy agent (cisplatin), which may contribute to the decreased cancer mortality rates found among those who exercise regularly. Similar to the cellular effects, changes to serum cytokine levels – several of them linked to the senescence-associated secretory phenotype – depended on whether serum was conditioned by acute or by chronic exercise.”
Scientists discover why this deadly lung cancer keeps coming back
“Small cell lung cancer (SCLC) is among the most aggressive types of lung cancer, with a five-year survival rate of just five percent. Although it often responds well to chemotherapy at first, that success is usually short lived. Most patients experience a relapse, followed by rapid disease progression. Because of this pattern, understanding the biology behind SCLC is critical for extending treatment benefits, preventing relapse, and improving long term outcomes.”
Researchers identify genes for predicting lung cancer recurrence
“Researchers from Boston University Chobanian & Avedisian School of Medicine believe they have, for the first time, identified genes whose activity changes in lung tumors with vascular invasion. Additionally, they also discovered that they could detect these changes in small pieces of the tumor collected during a presurgical biopsy procedure.”
First-in-Class Investigational Drug KRAS G12D Degrader Shows Promise in Lung and Pancreatic Cancers
“Results from the trial were published in the New England Journal of Medicine, in March 2026. The study demonstrated benefit and safety in both lung and pancreatic cancers that had gotten worse on prior treatments. About a third of the patients with metastatic lung cancer responded to setidegrasib with encouraging durability, which means the length of time the drug stays effective. About 60% of the lung cancer patients were alive after one year.”
Nucleosome Liquid Biopsy Shows Promise for Lung Cancer Risk Stratification
“The poster presentation highlighted the use of Volition’s Nu.Q Cancer assays, which measure H3K27Me3-nucleosome levels from a simple blood draw, to predict recurrence-free and overall survival outcomes in lung cancer patients before surgery.”
Lung Cancer Patients Can Safely Receive Half the Usual Radiation Dose — in Just One Treatment
“6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment.”
Low-Dose CT Screening Reduces Lung Cancer–Specific Mortality
“The use of low-dose CT screening correlated with lower lung cancer–specific mortality in a non–risk-based lung cancer population, according to findings from the Lung-Care Project (NCT04938804) presented at the 2026 European Lung Cancer Congress.”
Adding Chemo to Osimertinib Doubles PFS in EGFR-Mutated NSCLC With TP53 Mutations
““These findings provide key evidence to support a molecular risk-guided individualized treatment strategy for EGFR-mutated non-small cell lung cancer,” Dr. Yang said during a proffered paper session (Abstract 20).”
Can marijuana cause lung cancer?
“As more states legalize marijuana, many people might be wondering if that means it is safe to use. While smoking tobacco is a known and well-studied cause of lung cancer, linking marijuana to cancer is more complicated, says Brooks Udelsman, MD, a thoracic surgeon with USC Surgery, part of Keck Medicine of USC.”
Hernexeos Shows Strong Responses in HER2 Non-Small Cell Lung Cancer
“Researchers reported at the 2026 European Lung Cancer Congress that Hernexeos (zongertinib) led to high response rates and disease control in patients with advanced HER2-mutant non–small cell lung cancer (NSCLC), including those with active brain metastases, addressing an unmet need for targeted first-line treatment options in this population.”
Vaping Likely Causes Cancer, Major Study Finds
“Nicotine vaping is likely to cause lung and oral cancers, a comprehensive review of more than 100 studies has concluded. According to the analysis, human and animal studies, as well as cell experiments looking at the effects of chemicals found in vape liquid, all point toward carcinogenicity. Those studies, published since 2017, record “increasing concern”, the researchers report.”
Nivolumab-Based Treatment Yields Long-Term Survival in Resectable NSCLC
“Perioperative nivolumab (Opdivo)-based treatment demonstrated long-term survival among patients with resectable stage IIA to IIIA non–small cell lung cancer (NSCLC), especially among those with a pathological complete response (pCR), according to findings from a phase 2 trial (NCT04015778) presented in a poster session at the 2026 European Lung Cancer Congress.”
